For the individuals studied here, increased levels of CKAP4 may not be driving disease, but the finding opens a potential line of anti-CKAP4 antibody drug development for SLE patients; an avenue previously only promoted for cancer treatment34. Here, CKAP4 is linked to systemic lupus erythematosus.